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Abstract
We have determined the kinetic parameters for stimulation and inhibition by 34 drugs of the P-glycoprotein ATPase in
membranes derived from CR1R12 Chinese hamster ovary cells. The drugs chosen were sets of calmodulin antagonists,
steroids, hydrophobic cations, hydrophobic peptides, chemotherapeutic substrates of P-glycoprotein, and some other drugs
with lower affinity for P-glycoprotein. We studied how these kinetic parameters correlated with the partition coefficient and
the Van der Waals surface area of the drugs. The maximum velocity of ATPase stimulation decreased with surface area and
showed a suggestion of a maximum with increasing partition coefficient. The affinity of these drugs for P-glycoprotein
showed no significant correlation with partition coefficient but was highly correlated with the surface area suggesting that
binding between modulators and P-glycoprotein takes place across a wide interaction surface on the protein.
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1. Introduction
In the preceding paper of this series Litman et al.
ATPase activity of P-glycoprotein related to emer-
gence of drug resistance in Ehrlich ascites tumor cell
.lines, BBA, this issue , we characterized the modula-
tion of the ATPase activity of P-glycoprotein derived
from multidrug resistant Ehrlich ascites tumor cells
for nine different drugs. In order to provide insight
into the mechanism whereby P-glycoprotein interacts
) Corresponding author. Department of Medical Physiology,
The Panum Institute, University of Copenhagen, Blegdamsvej 3,
 .DK-2200 Copenhagen N, Denmark. Fax: 45 -3532 7420. Email:
T.Litman@mfi.ku.dk
with its modulators we have extended this study to a
total of 34 different drugs and performed a QSAR
 .quantitative structure-activity relationships analysis
using the molecular mechanics programs ChemPluse
and HyperChemw. The QSAR parameters obtained
are based on calculations of minimum energy confor-
mations of the drugs, and have been compared to
parameters which describe the affinity for and stimu-
lation of the P-glycoprotein ATPase. It has been
suggested that effective MDR modulators share phys-
w xical properties such as octanolrwater partitioning 1
w x w xand molecular size 2 and shape 3,4 . Partitioning is
w xof key importance in vivo behavior of xenobiotics 5 ,
and is most often described by log P reviewed by
w x.Leo et al. 6 , but also other parameters reflecting
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bulk, such as molecular weight, volume, refractivity,
w xand Van der Waals surface area 7 have proven to be
important variables in QSAR analysis. All these pa-
rameters have been calculated for the test panel of
drugs.
In the present study, the source of P-glycoprotein
was the microsomal membrane fraction prepared from
a highly drug resistant, P-glycoprotein-overproducing
CHO cell line, CR1R12. This cell line constitutively
overexpresses P-glycoprotein, which amounts to a
 .maximum of 32% wrw of the total plasma mem-
w xbrane protein 8 . Thus, the CR1R12 cell line pro-
vides an excellent source of membranes enriched in
P-glycoprotein, and enables a characterization of the
P-glycoprotein associated ATPase activity.
For all ATPase assays, the microsomal membrane
fraction of CR1R12 cells was used with no further
purification or reconstitution steps. This approach
was chosen for five reasons. First, the signal-to-noise
ratio was sufficiently high in the microsomal fraction
to obtain an adequate drug-modulatable ATPase ac-
tivity pattern. Second, in the crude membrane frac-
tion, the activity of P-glycoprotein is assayed in its
genuine, ‘natural’ microenvironment, with minimal
risk of perturbation of the system. Third, it is now
known that some of the common protease inhibitors
employed in reconstitution, such as leupeptin and
pepstatin A, themselves are substrates of P-glyco-
w xprotein 9 and thus would tend to pre-activate the
P-glycoprotein ATPase. Fourth, the major problem in
any reconstitution procedure: the use of detergents
e.g. deoxycholate, digitonin, SDS, Triton X-100,
.CHAPS which have been shown to inactivate P-
w xglycoprotein, even at very low concentrations 10,11 ,
is avoided. Fifth, the introduction of an artificial lipid
environment, the composition of which can greatly
affect the characteristics of reconstituted P-glyco-
w xprotein 11–14 , is evaded by using the P-glyco-
protein enriched, microsomal membrane fraction.
We have characterized the kinetic parameters de-
scribing the activation and inhibition of the P-glyco-
protein ATPase for all 34 drugs and have analyzed
how the parameters for activation depend on the
partition coefficient and Van der Waals surface area
of the various drugs. Our results can form the basis of
a strategy for improving the design of modulators of
P-glycoprotein with the aim of developing more ef-
fective cancer chemotherapeutics.
2. Materials and methods
2.1. Tumor cells
The Chinese Hamster Ovary cell line, CHO
CR1R12 kindly made available for us by Dr Alan E.
Senior, University of Rochester Medical Center, New
.York, USA , was used. The cells were maintained in
 .a-MEM minimal essential medium containing 10%
fetal calf serum and 5 mgrml colchicine. In order to
obtain a high yield of cells for the subsequent mem-
brane preparation, the cells were grown in ‘cell-facto-
 .ries’ Nunc, Roskilde, Denmark , and were harvested
by a standard trypsinization procedure.
2.2. Isolation of microsomal membranes
The cells were washed with Ringer’s medium
NaCl, 148.7 mM; K HPO , 2.55 mM; KH PO ,2 4 2 4
.0.45 mM; MgSO , 1.2 mM; pH 7.4 before being4
resuspended in 10 ml lysis buffer Hepes-Tris, 10
mM; EDTA, 5 mM; EGTA, 5 mM; dithiothreitol, 2
. mM; pH 7.4 containing protease inhibitors phenyl-
methylsulfonyl fluoride, 2 mM; aprotinin, 5 mgrml;
.pepstatin, 10 mgrml; leupeptin, 10 mgrml . This
and all subsequent steps were performed at 48C. Cells
were lysed by nitrogen cavitation Parr Instrument
.Co., Moline, IL, USA at 1200 psi for 20 min. Nuclei
were sedimented by centrifugation at 300=g for 10
min, and subsequently mitochondria were removed
by centrifugation at 4000=g for 10 min. In a third
 .and final centrifugation 45 000=g, 60 min the
microsomal fraction was sedimented. The pellet was
resuspended in 1 ml of lysis buffer and homogenized
by aspiration ten times through a 27 gauge syringe.
 .Aliquots of 150 ml containing 1–2 mg proteinrml
were frozen in N and stored at y808C.2l.
2.3. ATPase acti˝ity assay
The P-glycoprotein associated ATPase activity was
w xdetermined according to Borgnia et al. 15 , by quan-
titating the release of inorganic phosphate from ATP.
The microsomes were thawed on ice before diluting
to a protein concentration of 20 mgrml in ice-cold
ATPase assay medium ATP, 3 mM; KCl, 50 mM;
MgSO , 2.5 mM; dithiothreitol, 3 mM; Tris-HCl, 254
. mM; pH 7.0 containing 0.5 mM EGTA to inhibit
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Fig. 1. ATPase activity of microsomes prepared from sensitive
 .  .EHR2 and multidrug resistant Ehrlich EHR2r1.3 and CHO
 .CR1R12 cells. The bars indicate the rate of ATP hydrolysis
 .  .nmolrminrmg protein in the absence of drug CTRL , with 25
 .  .mM verapamil VER , or 500 mM vanadate VO in the incuba-4
tion medium the vanadate bars are representative for experi-
.ments both with and without verapamil . Values are means"
 .S.E.M. ns3–6 .
. Ca-ATPases , 2 mM ouabain to inhibit the NarK-
. ATPase , and 3 mM azide to inhibit mitochondrial
.ATPase . Each series of experiments was carried out
in a 96-well microtiter plate, with reaction volumes
of 50 mlrwell corresponding to 1 mg proteinrwell.
Incubation with the various drugs was started by
transferring the plate from ice to 378C for 1 h, and
terminated by addition of 200 ml ice-cold stopping
  .medium ammonium molybdate, 0.2% wrv ; sulfu-
 .  .ric acid, 1.3% vrv ; SDS, 0.9% wrv ; trichloro-
 .acetic acid, 2.3% wrv ; freshly prepared ascorbic
 ..acid, 1% wrv to each well. After 30 min incuba-
tion at room temperature, the released phosphate was
quantitated colorimetrically in a micro-plate reader
 .Bio-Tek Instruments, VT USA at 620 nm. Samples
incubated with 500 mM vanadate inhibiting the P-
.glycoprotein ATPase were obtained in parallel and
subtracted from the measurements. Water-insoluble
drugs were dissolved in ethanol or DMSO, the sol-
 .vent constituted max. 1% vrv of the total volume.
2.4. Chemicals
All chemicals were of analytical grade, purchased
 .either from Merck Darmstadt, Germany or from
 .Sigma St. Louis, USA . D-verapamil and "-
verapamil were kindly provided by Knoll AG
 .Ludwigshafen, Germany , PSC-833 was a kind gift
 .from Sandoz now Novartis, Basel, Switzerland . All
Fig. 2. P-glycoprotein ATPase activity as a function of temperature. Left panel, D-verapamil activated ATPase activity of CR1R12
microsomes at 22, 30, 37, and 408C. The lines drawn are fitted to a modified form of the Michaelis-Menten equation taking into account
( ) )both the ascent and the decline of the ATPase activity curve. Right panel, the corresponding Arrhenius plot: ln ks ln AI E rRT .
log of the basal activity, V , the maximum stimulated activity, V , and the increase in activity, V yV , as a function of the reciprocal ofe 0 1 1 0
the absolute temperature is depicted. The lines are first order regressions to the data, the slopes of which give the activation energies:
E) s77.2 kJrmol, and E) s72.9 kJrmol.V1 V1yV0
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Fig. 3. Effect of calmodulin antagonists on the ATPase activity of
 .  .P-glycoprotein: pimozide v , trifluoperazine ^ , fluphenazine
 .  .  .’ , triflupromazine \ , chlorpromazine % , and prometha-
 .zine B . For clarity, the error bars are hidden.
other chemicals were of analytical grade, purchased
 .either from Merck Darmstadt, Germany or from
 .Sigma St. Louis, USA .
3. Results
3.1. Specific ATPase acti˝ity
In the preceding paper of this series Litman et al.,
ATPase activity of P-glycoprotein related to emer-
Fig. 4. Effect of steroids and a hormonal analogue on the ATPase
 .  .activity of P-glycoprotein: progesterone ‘ , spironolactone v ,
 .  .fucidin ^ , and tamoxifen ’ .
Fig. 5. Effect of hydrophobic cationic drugs on the ATPase
 .  .activity of P-glycoprotein: dipyridamole v , amiodarone ‘ ,
 .  .  .  .propafenone ^ , quinidine ’ , reserpine \ , terfenadine % ,
 .and mefloquine B .
gence of drug resistance in Ehrlich ascites tumor cell
.lines, BBA, this issue we studied the ATPase activ-
ity of microsomes prepared from a sensitive and five
progressively resistant Ehrlich tumor cell lines. Fig. 1
shows the ATPase activity of membranes derived
from two members of this series together with corre-
sponding data from a highly P-glycoprotein express-
ing CHO cell line, CR1R12. The data are for mem-
 .branes in the absence of any additive CTRL , in the
 .presence of 25 mM verapamil VER , or 500 mM
Fig. 6. Effect of hydrophobic peptides on the ATPase activity of
 .  .P-glycoprotein: cyclosporin A ‘ , PSC-833 v , valinomycin
 .  .^ , and gramicidin S ’ .
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 .vanadate VO . For all three cases vanadate inhibits4
the ATPase, for the resistant lines verapamil stimu-
lates the activity, but the CR1R12 membranes have
by far the greatest, specific ATPase activity. This cell
line constitutively overexpresses P-glycoprotein,
 .which amounts to a maximum of 32% wrw of the
w xtotal plasma membrane protein 8 . Thus, the CR1R12
cell line provides an excellent source of membranes
enriched in P-glycoprotein, and enables a characteri-
zation of the P-glycoprotein associated ATPase activ-
ity. We here investigate the P-glycoprotein associated
ATPase activity with respect to substrate specificity
and drug modulation pattern.
3.2. Acti˝ation energy for the ATPase reaction
A typical drug-activation pattern, in this case for
verapamil at four different temperatures, is depicted
in Fig. 2A. The ATPase activity profile is a character-
istic bell-shape, indicating the presence of two bind-
ing sites for the drug; one of high affinity, activating,
and the second, low-affinity site, inhibiting the AT-
Pase activity. As in the preceding paper the data are
 .fitted solid lines to the equation:
K K V qK V SqV S21 2 0 2 1 2V s 1 .S. 2K K qK SqS1 2 2
where V is the ATPase activity as a function of theS.
substrate concentration S, V is the basal activity the0
Fig. 7. Effect of vinca alkaloids and anthracyclines on the
 .ATPase activity of P-glycoprotein: vinblastine ‘ , vincristine
 .  .  .v , daunorubicin ^ , and epirubicin ’ .
Fig. 8. Two drugs that show no apparent modulation of the
 .  .P-glycoprotein ATPase: colchicine ‘ and methotrexate v .
.activity in the absence of modulator , V is the1
 .maximal enzyme activity if only activation occurred ,
and K is the substrate concentration that gives half1
this maximal increment in ATPase activity. V is the2
activity at infinite concentration of the modulator,
and K is the substrate concentration which gives2
half-maximal reduction of ATPase activity from the
value V .1
Fig. 2B is an Arrhenius plot of the basal activity
 .  .V , the maximal activity V , and the increase in0 1
 .activity V yV as a function of the reciprocal of1 0
the absolute temperature. The lines drawn are first
order regressions to the data, the slopes of which give
the activation energy, which was 77.2 kJrmol for V1
and 72.9 kJrmol for V yV . This is the first time1 0
that data have been presented on the activation en-
ergy of the P-glycoprotein ATPase. The values found
compare well with the value of 71 kJrmol for ATP
hydrolysis by the NaqrKq-ATPase from guinea-pig
w xkidney 16 and with the activation energy of 70
kJrmol for the myosin ATPase from rabbit muscles
w x17 .
3.3. ATPase acti˝ity profiles for 34 drugs
We have characterized the ATPase activity profiles
for 34 drugs. Figs. 3–8 depict these data for various
classes of modulators: The calmodulin antagonists
 .  .Fig. 3 , steroids Fig. 4 , hydrophobic cationic drugs
 .  .Fig. 5 , hydrophobic peptides Fig. 6 , chemothera-
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 .peutic substrates of P-glycoprotein Fig. 7 , and two
drugs that show no apparent modulation of the AT-
 .Pase Fig. 8 .
 .We found for all 34 drugs, that Eq. 1 gave a
statistically better fit to the data than a simple one-site
Michaelis-Menten equation. In all except one case
 .PSC-833 the improvement of the fit was better at
P-0.025, and for PSC-833 the improvement was
better at P-0.1. Table 1 summarizes the kinetic
parameters derived from this analysis.
3.4. Structure-acti˝ity relationships
We first asked whether there was any relationship
between the kinetic parameters and the partition coef-
ficients for the various drugs. Fig. 9 depicts a plot of
 .  .1rK Fig. 9A and of V Fig. 9B versus log of the1 1
 .octanol-water partition coefficient P . These partition
coefficients were estimated on the basis of atomic
w xparameters derived by Ghose and Crippen 18 . The
straight line in each figure is the linear regression.
Table 1
Kinetic parameters for P-glycoprotein associated ATPase activity as a function of different drugs and drug concentrations
2 2 .  .Drug Ys K K V qK V SqV S r K K qK SqS , V s11 2 0 2 1 2 1 2 2 0
 .  .  .  .V fold V fold K mM K mM1 2 1 2
" -Verapamil 2.1 0.6 2.5 98.5
D-verapamil 2.1 0.4 1.6 164
Dipyridamole 1.9 1.3 0.4 190
Diltiazem 3.3 0 73.3 677
Fluphenazine 2.1 0.7 11.3 28.8
Trifluoperazine 2.0 0.6 6.5 24.1
Triflupromazine 2.0 0.8 15.7 59.2
Chlorpromazine 1.8 0.6 12.2 80.9
Amiodarone 2.0 0.4 3.2 7.2
Pimozide 1.6 0.2 1.0 11.1
Propafenone 2.0 0 4.2 632
Quinidine 1.6 0 5.0 1187
Amitriptyline 2.3 0.9 108 110
Promethazine 1.8 0 23.4 1770
Progesterone 2.6 0.3 17.5 294
Spironolactone 1.9 0.4 3.9 451
Reserpine 1.3 0.02 0.1 50.9
S-Propranolol 2.1 0.9 170 551
Terfenadine 1.6 0.4 2.2 8.1
Fucidin 1.2 0.2 4.2 129
Mefloquine 2.1 0.4 3.8 9.2
Tamoxifen 1.8 0.1 0.1 11.9
Cyclosporin A 1.06 0.6 0.06 1.7
PSC-833 0.6 0.3 0.03 0.7
Valinomycin 2.3 0 0.03 16.1
Gramicidin S 1.03 0.2 0.09 0.4
Vinblastine 1.5 0.5 1.3 17.3
Vincristine 1.1 0.7 0.2 12.9
Daunorubicin 1.08 0.6 0.3 18.2
Epirubicin 1.05 0.8 0.2 22.8
1Colchicine 1.08 1.08 842 1010
2Methotrexate 0.9 0.9 575 4625
The relative ATPase activity of CR1R12 derived microsomes has been used for the curve fits, applying the Marquardt-Levenberg
algorithm. 1 The activity did not decline, even at the highest drug concentration. 2 The activity did not change with drug concentration,
hence, the fit reflects random fluctuations only.
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 .  .  .Fig. 9. Correlation between A 1rK for ATPase stimulation log scale and log P, and B maximal ATPase activity V and log P.1 1
 .  .  .  .  .  .Symbols: verapamil v ; calmodulin antagonists ^ : pimozide a , fluphenazine b , promethazine c , chlorpromazine d ,
 .  .  .  .  .  .  .trifluoperazine e , triflupromazine f ; hydrophobic cationic drugs \ : reserpine g , quinidine h , dipyridamole i , propafenone j ,
 .  .  .  .  .  .  .mefloquine k , amiodarone l , terfenadine m ; steroids and tamoxifen I : spironolactone n , progesterone o , fucidin p , tamoxifen
 .  .  .  .  .  .  .  .q ; low affinity drugs ‘ : propranolol r , diltiazem s , amitriptyline t ; anthracyclines e : epirubicin u , daunorubicin v ; vinca
 .  .  .  .  .  .  .alkaloids hexagons : vincristine w , vinblastine x ; hydrophobic peptides q : cyclosporin A y , gramicidin S z , valinomycin æ .
 .The straight lines are first order regression lines; the dotted line B accentuates the trend in the series of hydrophobic cationic drugs.
The correlation coefficient for 1rK on log P is1
0.206, and for V on log P is 0.099, neither of which1
is significant. However, it could be argued, that
 .except for one point p, fucidin , V rises with log P1
to a maximum at log Ps4.3 and then falls again.
 .Fig. 10 depicts a similar plot of 1rK Fig. 10A and1
 .of V Fig. 10B versus the Van der Waals surface1
area, again estimated according to the procedure of
w xGhose and Crippen 18 . The solid straight line is the
linear regression. The correlation coefficient for 1rK1
 .  .  .Fig. 10. Correlation between A 1rK log scale for ATPase stimulation and Van der Waals surface area, and B maximal ATPase1
activity V versus Van der Waals surface area. The same symbols as in Fig. 9 apply. The straight lines are first order regressions; the1
 .dotted lines A are regression lines for the series of hydrophobic cationic drugs and the calmodulin antagonists.
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on surface area is 0.753, which is significant at
P-0.01. The dotted lines are regressions through
two subsets of closely related chemical structures: the
phenothiazines of Fig. 3, and the hydrophobic cations
of Fig. 5. In both series 1rK increases with surface1
area.
The plot of V versus surface area is depicted in1
Fig. 10B. The straight line is the linear regression of
negative slope with a correlation coefficient of 0.494,
significant at P-0.01.
4. Discussion
The mechanism by which a wide variety of struc-
turally and physically unrelated drugs are able to
interact with P-glycoprotein is essentially unknown
w x19 . The structure-function relationship of chemosen-
sitizers has been put into focus, because such knowl-
edge might lead to design of more efficient inhibitors
of P-glycoprotein. However, so far, it has not been
possible to identify any structural features, which
were strongly correlated with the reversing capacity
w x w xof the compounds 20 . Chiba et al. 3 examined a
series of propafenone derivatives; no stereoselectivity
was observed, a tertiary amino group enhanced the
effectiveness, and the highest activity was seen with
compounds having three aromatic groups and a piper-
azine moiety. However, none of these compounds
were as potent as the reference substance, verapamil.
w xPearce et al. 21 reached a somewhat similar conclu-
sion by studying a series of reserpine analogs, in
which the arrangement of aromatic groups and a
basic nitrogen atom determined the activity. Gros and
w xco-workers 2 employed a series of colchicine analogs
to identify structural determinants that are required
for recognition by P-glycoprotein, and found that
both a minimal size and a nitrogen atom at the
acetamido group of colchicine are essential for effi-
cient interaction with P-glycoprotein. In a study of
the structural features of phenothiazines Ford et al.
w x22 emphasized the importance of a hydrophobic
w xcore for the ‘ideal reverser’. Zamora et al. 1 investi-
gated a wide range of modulators, and found that the
reversing potential was best correlated to the oc-
tanolrwater partition coefficients of the drugs. This
w xfinding was confirmed by Pearce et al. 4 , who found
the strongest reversers to be the most hydrophobic,
and suggested that ‘‘structural similarities between
different classes of compounds are present in com-
pounds recognized by the MDR phenotype’’, thus
emphasizing the importance of a ligand-receptor rela-
tionship for the reversers of P-glycoprotein.
While in most of the above studies a specific
interaction between the modulator and some binding
site on P-glycoprotein is assumed, other investigators
have suggested that the chemosensitizing ability of
many modulators is primarily due to their nonspecific
w xmembrane perturbing effect 23–25 , like the sensitiz-
w x w xing action of detergents 26 and surfactants 27 on
MDR cells. Since P-glycoprotein is a membrane-
spanning protein, one would expect its transport func-
tion to be affected by the physical properties of the
membrane and of the surrounding lipid environment
w x28 . Therefore, the possible membrane interactions
of MDR modulators should not be neglected when
w xanalyzing the mechanism of action of the drugs 23 .
However, when examining the concentration depen-
dence of resistance reversal, it appears that most of
the reversers efficiently inhibit P-glycoprotein medi-
ated transport at concentrations which are lower than
those which cause membrane perturbations. For ex-
ample, verapamil has a K of 47 mM for displace-i
w xment of rhodamine 6G from phospholipids 23 , while
the concentrations which reverse MDR are in the
w xrange 1–10 mM 19,29,30 .
The aim of this study was to discern any trends in
P-glycoprotein ATPase modulating ability of a series
of 34 drugs, varying in structure as well as in biologi-
cal activity. To this end, we have performed a com-
plete kinetic analysis to separate out the effects of
structural variables on the affinity and maximum
 . velocity of the ATPase Table 1 . In most cases 25
.out of 34 , stimulation of the P-glycoprotein associ-
ated ATPase activity developed at low drug concen-
trations and was describable by simple Michaelis-
 .Menten saturation kinetics Figs. 2–8 . However, at
higher substrate concentrations, marked inhibition of
the ATPase activity consistently occurred all drugs,
.excepting propranolol . This characteristic biphasic
response strongly suggests that at least the activation
of the P-glycoprotein ATPase is a specific effect due
to direct interaction between the substrate and the
catalytic sites of P-glycoprotein. Whether the decre-
ment in activity observed at higher drug levels was
due to a nonspecific membrane-altering effect or
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whether it reflected interaction with a low-affinity
inhibitory site at P-glycoprotein is at present not
clear. For those drugs that elicited inhibition of AT-
Pase activity at relatively low concentrations K2
around 1 mM: cyclosporin A, PSC-833, gramicidin D
.and S this effect was in all probability due to
specific interactions with P-glycoprotein. Most drugs,
however, caused inhibition at concentrations between
10 and 1000 mM, and such high levels are likely to
be associated with nonspecific perturbation of the
membrane structure. This conclusion was supported
by experiments with microsomes prepared from drug
 .sensitive Ehrlich ascites cells data not shown , the
ATPase activity of which was also decreased by
those drugs the phenothiazines, amiodarone, reser-
.pine, terfenadine, fucidin, and tamoxifen that had a
noticeable inhibitory effect on P-glycoprotein con-
taining membranes.
The fact that a number of drugs showed ATPase
activity profiles similar to those of daunorubicin and
 .gramicidin S Fig. 2 shows that these drugs are able
to reduce the ATPase activity below the basal level.
This suggests that basal activity is, at least in part,
due to P-glycoprotein. This conclusion is reinforced
by our finding that both the basal activity and the
drug-stimulated activity are greatly enhanced in the
highly P-glycoprotein expressing CR1R12 cell line.
 .The majority of the drugs 28 out of 34 had high
affinity for the P-glycoprotein ATPase, with an ap-
parent K between 0.1–10 mM, supporting the viewm
that drug-modulated ATPase activity is reflecting
specific drug-protein interactions. A few substances
had relatively high K values, namely diltiazem 41m
.  .  .mM , amitriptyline 46 mM , propranolol 72 mM ,
 .and in particular colchicine 775 mM .
w xOur data support the findings of Pirker et al. 31
and suggest that stereospecificity is not a feature of
P-glycoprotein. Thus, the kinetic parameters of AT-
Pase activity stimulation for both the racemate and
the enantiomers of verapamil were not different, and
the same was tue for the R- and S-enantiomers of
propranolol.
w xContrary to the findings of Zamora et al. 1 and of
w xPearce et al. 4 we find no statistically significant
dependence of either of the two kinetic parameters
 .  .1rK Fig. 9A or V Fig. 9B on partition coeffi-1 1
cient We use 1rK rather than K in Fig. 9AFig.1 1
10A because it is the reciprocal of the Michaelis
constant, Km, which is directly proportional to affin-
 .ity, and we plot log 1rK rather than 1rK , be-1 1
 .cause log 1rK is directly proportional to the free1
.energy of interaction between ligand and receptor .
Even if we consider the three series of structurally
related compounds that appear in our data set, we
find no consistent variation of 1rK with log P. If,1
however, we look at V versus log P, the data for the1
 .hydrophobic drugs dotted line in Fig. 9B show a
clear maximum for mefloquine. This agrees well with
w x‘Ferguson’s principle’ 5 which states that biological
potency increases with partition coefficient until an
optimum value is reached, after which a fall-off in
activity is observed, probably as a result of limiting
aqueous solubility.
What we do find, is a very clear correlation of the
affinity of the modulators with their Van der Waals
surface area. The data as a whole solid line in Fig.
.  .10A , and the individual series dotted lines , show
 .good linear dependence of log 1rK on the Van der1
Waals surface area. This suggests that binding be-
tween modulators and P-glycoprotein takes place
across a wide interaction surface on the protein.
Considering now, the maximum velocity of AT-
Pase activity, here we find an overall decrease with
 .increasing surface area excepting valinomycin . This
would be expected if it was the de-binding of the
ligand that was the rate-limiting step for the overall
ATPase activity, but it would also be the case if a
rate-limiting conformational change of the enzyme
was impeded by a bulky substrate.
The good correlation between affinity and molecu-
lar size would seem to be an important finding, since
it partly accounts for the lack of specificity of P-
glycoprotein. These findings favor a model of P-
glycoprotein with ‘pliable’ domains as suggested by
w xSehested 32 , e.g. a large drug-binding region, rather
than multiple high-affinity sites.
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